Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details Narrative)

v3.20.2
Stockholders' Equity (Details Narrative) - USD ($)
 9 Months Ended
Oct. 06, 2020
Jun. 18, 2020
Sep. 30, 2019
Sep. 30, 2020
Jun. 25, 2020
Jun. 24, 2020
Dec. 31, 2019
Common stock, shares authorized       30,000,000 30,000,000 100,000,000 100,000,000
Preferred stock, shares issued          
Preferred stock, shares outstanding          
Public Offering [Member] | Subsequent Event [Member]              
Number of common stock issued during period 4,800,000            
Price per share $ 4.00            
Proceeds from offering $ 17,100,000            
Follow on Public Offering [Member] | Subsequent Event [Member]              
Number of common stock issued during period 3,270,095            
Pledge Agreement with PoC [Member]              
Clinical trial funding commitment     $ 1,800,000        
Reduced clinical trial funding commitment     $ 900,000        
Number of pledged shares forfeited     56,640        
Warrants to purchase common stock, forfeited     56,640        
2018 Private Placement Transactions [Member]              
Debt conversion price per share       $ 14.28      
Number of common stock issued during period       28,971      
2018 Private Placement Transactions [Member]              
Number of common stock issued during period   28,971